HC Wainwright Estimates Harrow’s Q2 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – HC Wainwright reduced their Q2 2026 earnings estimates for Harrow in a research report issued to clients and investors on Thursday, May 14th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.01 per share for the quarter, down from their previous forecast of $0.10. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is $0.37 per share. HC Wainwright also issued estimates for Harrow’s Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $0.15 EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at $0.40 EPS, Q4 2027 earnings at $1.06 EPS and FY2027 earnings at $1.14 EPS.

Several other brokerages have also commented on HROW. Nomura lowered shares of Harrow to a “neutral” rating in a research note on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Tuesday, May 12th. B. Riley Financial restated a “buy” rating and issued a $65.00 price target (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, Wall Street Zen lowered shares of Harrow from a “hold” rating to a “sell” rating in a research note on Saturday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $69.43.

Harrow Price Performance

HROW opened at $30.90 on Tuesday. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -75.36 and a beta of 0.34. Harrow has a fifty-two week low of $25.21 and a fifty-two week high of $54.85. The company’s 50-day moving average price is $36.41 and its 200 day moving average price is $42.11. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The business had revenue of $44.20 million for the quarter, compared to analyst estimates of $52.43 million. Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.During the same quarter last year, the company earned ($0.38) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. University of Texas Texas AM Investment Management Co. bought a new position in shares of Harrow in the fourth quarter valued at approximately $26,000. KBC Group NV bought a new position in shares of Harrow in the first quarter valued at approximately $31,000. Raymond James Financial Inc. bought a new position in shares of Harrow in the second quarter valued at approximately $48,000. SBI Securities Co. Ltd. boosted its holdings in shares of Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after acquiring an additional 846 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of Harrow in the third quarter valued at approximately $83,000. 72.76% of the stock is currently owned by institutional investors.

Insider Activity at Harrow

In other news, CFO Andrew R. Boll purchased 3,500 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were bought at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the purchase, the chief financial officer owned 814,679 shares of the company’s stock, valued at $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.80% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.